- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07940452
A Novel Eye Wash Solution for DED Treatment
A single-center, randomized, participant-masked, placebo-controlled, parallel-group clinical trial designed to evaluate the effectiveness and safety of a novel eye wash solution for the treatment of dry eye disease
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase inicial 1
Contactos e Locais
Contato de estudo
- Nome: Jiaxu Hong, Department chief
- Número de telefone: 021-64377134
- E-mail: Jiaxu.hong@fdeent.org
Locais de estudo
-
-
-
Shanghai, China
- Fudan Eye, Ear, Nose and Throat Hospital
-
Contato:
- Jiaxu Hong
- Número de telefone: 021-64377134
- E-mail: Jiaxu.hong@fdeent.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age of at least 18 years at the time of signing the informed consent. Provision of written informed consent.
- Tear film break-up time (TBUT) < 10 seconds at both Visit 0 and Visit 1. Ocular Surface Disease Index (OSDI) score ≥ 13 at both Visit 0 and Visit 1. Meibomian gland dysfunction (MGD) score ≥ 3 at Visit 0 or Visit 1.
- Presence of cloudy meibum; or 3 or 4 out of 5 meibomian glands expressible upon eyelid compression; or meibomian gland dropout count ≥ 5 at both Visit 0 and Visit 1.
- Meibomian gland dysfunction scoring: MGD is scored based on the secretion of the central 5 meibomian glands of the lower eyelid. Each gland is scored from 0 to 3 (0 = normal; 1 = thick, yellow-white particles; 2 = paste-like secretion; 3 = no secretion or obstruction), with a total score of 0-15 [12].
- Total corneal fluorescein staining score of 1 < X < 10 (sum of inferior, superior, central, nasal, and temporal regions) according to the National Eye Institute (NEI) grading system at both Visit 0 and Visit 1.
- At both Visit 0 and Visit 1, at least one eye (the same eye) must meet all criteria of items 3, 4, 5, and 6 above.
- Ability and willingness to follow instructions, including participation in all study assessments and visits.
Exclusion Criteria:
- Any clinically significant abnormal findings on slit-lamp examination of the ocular surface at both Visit 0 and Visit 1, or any findings that, in the investigator's judgment, may affect study parameters, which may include ocular trauma, history of ocular trauma, or anterior membrane disease.
- History of Stevens-Johnson syndrome; use of any oral medications known to cause dry eyes (e.g., antihistamines, antidepressants, etc.) within 1 month prior to Visit 0, or expected instability during the study period.
- Active ocular infection; use of any topical antibiotics or topical steroids within 14 days prior to the visit, or potential need for such treatment during the study. Any other eyelid margin treatments, such as meibomian gland expression, systemic antibiotics (e.g., tetracyclines), and oral supplements for eye diseases (e.g., lutein) must remain stable for 14 days prior to the visit and throughout the study period.
- Receipt of LipiFlow, intense pulsed light (IPL), or any other procedures affecting the meibomian glands within 1 month prior to Visit 1.
- Abnormal eyelid structure preventing complete eyelid closure, including entropion, ectropion, or floppy eyelid syndrome, which may cause partial conjunctival exposure or affect eyelid blinking function.
- Placement or removal of a permanent punctal plug within 3 months prior to Visit 1 (or 6 months for dissolvable plugs); or expected placement or removal of a punctal plug at this visit, or expected dissolution of the punctal plug during the study.
- Dry eye caused by scarring, radiation injury, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (commonly seen in vitamin A deficiency).
- Ocular or periocular malignancy.
- Corneal epithelial defect; significant confluent staining or filaments in any part of the cornea.
- History of herpes keratitis.
- Significant ocular allergy symptoms, or expected persistent allergic conditions during the study.
- Diagnosis of active ocular or systemic infection (bacterial, viral, or fungal) accompanied by fever requiring antibiotic treatment.
- Use of contact lenses within 14 days prior to Visit 0, or expected use of contact lenses during the study.
- Any intraocular, corneal, or ocular laser surgery within the past 6 months, or any planned ocular and/or eyelid surgery during the study.
- Employees of the clinical trial site directly involved in the management, administration, or support of this trial, or immediate family members of the same trial site.
- Women who are pregnant, breastfeeding, or planning to become pregnant.
- For women of childbearing potential, refusal to undergo urine pregnancy testing at Visit 0, Visit 1, Visit 2, and Visit 3 (or early termination visit) will be considered a refusal of testing. Non-childbearing potential is defined as permanently sterilized (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (no menstruation for 12 consecutive months).
- Women of childbearing potential not using effective contraception. Acceptable contraceptive methods include: hormonal oral contraceptives, implantable contraceptive devices, injectable contraceptives, or transdermal contraceptives; mechanical spermicides combined with barrier devices such as a diaphragm or condom; intrauterine devices; or surgical sterilization of the partner. For women who are not sexually active, abstinence may be considered an effective contraceptive method; however, if the subject becomes sexually active during the trial, she must agree to use appropriate contraception as defined above for the remainder of the trial.
- Presence of an uncontrolled systemic disease, in the investigator's judgment. Known allergic reaction to the investigational drug or its components. Significant ocular or periocular rosacea that, in the investigator's judgment, interferes with the trial (e.g., clinically significant facial induration).
- Pterygium in either eye.
- Current participation in an investigational drug or device study, or use of an investigational drug or device within 60 days after Visit 1.
- Non-use of any lipid-based artificial tears (e.g., perfluorohexyloctane ophthalmic solution, etc.), no application of warm compresses, and no use of any eye drops and/or "TrueTear™" device (intranasal tear neurostimulator) within 3 days prior to this visit.
- Presence of systemic immune diseases, such as systemic lupuserythematosus, rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, etc.
- Best-corrected visual acuity ≥ 4.3 in both eyes at Visit 0 and Visit 1 (5-point recording method on the international standard logarithmic visual acuity chart at 5 meters).
- Any condition or circumstance (including language barriers) that, in the investigator's judgment, may place the subject at significant risk, may interfere with study results, or may significantly hinder the subject's participation in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Braço placebo
|
Saline (NaCl 0.9 %), one drop per eye, 3 times daily (TID) for 28 days. |
|
Experimental: Eye Wash Solution Arm
|
0.2% DHA eye wash solution, one drop per eye, 3 times daily (TID) for 28 days. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Corneal Fluorescein Staining (CFS) Score
Prazo: Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in corneal fluorescein staining score (total score 0-15) in the study eye. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
|
Change in Ocular Surface Disease Index (OSDI) Score
Prazo: Baseline (Visit 1) to Day 28 (Visit 3)
|
Change from baseline in OSDI score (ranging from 0 to 100) to assess dry eye symptoms. |
Baseline (Visit 1) to Day 28 (Visit 3)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FDEENT-20261111
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .